FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending November 07, 2008
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 


Notification of Transactions of Directors, Persons Discharging 
Managerial Responsibility or Connected Persons


The a
dministrators of the GlaxoSmithKline Performance Share Plan
 (the "Administrators")
 notified the Company and 
the under
-mentioned
 person
s
 on 
7
 November
 2008
 
of 
an 
increase in 
th
eir notional 
interest
s
 
in 
Ordinary 
shares
 at a price of £
11.66
 per share
 and 
Ordinary 
Share
 ADRs at 
a price of $
37.32
 per ADR
 
following the notional re-investment of the dividend 
to be
 p
aid to shareholders on 8 January 2009
.


Ordinary 
shares
ADRs
Mr A 
P 
Witty
5
,
625.13

Mr J 
S 
Heslop
3,959.53

Dr M 
M 
Slaoui
352.25
1
,
835.07
Mrs C E Bruck Slaoui
28.07
41
.75
Mr S M Bicknell
296.63

Mr J
 M
 Clarke
2,952.21

Mr M Dunoyer
1,111.87

Mr E J Gray
921.57

Mr S A Hussain
545.32

Mr D Learmouth
607.10

Mr W C Louv

738.09
Mr D 
J 
Phelan

1,563.87
Dr D Pulman

1015.50
Mr D S Redfern
452.42

Mr J R Stéphenne 
1,019.86

Ms C Thomas
340.46




The Administrators 
also notified the Company on 
7 November 2008
 
of a further
 increase in the 
notional interests of the under-
mentioned persons in 
O
rdinary shares at a price of £11.67 following the notional re-investment of the dividend paid to shareholders on the 
9 October 2008
. 


Ordinary 
shares
Mr A 
P 
Witty
690.66
Mr A S Hussain
500.36



The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings 
that 
v
est
 following the end of the relevant three year measurement period.

This notification relates to 
transaction
s
 notified in accordance with
 
Disclosure
 and Transparency
 R
ule
s
 3.1.4R(1)(a)
.
 

Victoria A Whyte
Deputy 
Company Secretary

7
 November
 
2008

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: 07 November 2008

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc